$AVXL
Anavex Life Sciences Corp Stock $avxl

$avxl Overview Financials Valuation SEC Filings Company Website

2022 Q4 Form 10-K Financial Statement

#000173112222002062 Filed on November 28, 2022

Income Statement

Concept	2022 Q4	2022 Q3	2022
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$3.317M	$3.903M	$13.07M
YoY Change	8.15%	35.55%	44.94%
% of Gross Profit
Research & Development	$12.07M	$11.38M	$37.92M
YoY Change	39.4%	21.43%	14.95%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses	$15.38M	$15.28M	-$50.99M
YoY Change	31.22%	24.75%	-221.39%
Operating Profit	-$15.38M		-$50.99M
YoY Change	31.22%		21.39%
Interest Expense	$1.634M	$209.5K	$43.38K
YoY Change	2610.47%	-175.53%	-117.99%
% of Operating Profit
Other Income/Expense, Net	$2.392M	$994.3K	$3.366M
YoY Change	195.07%	4.31%	-26.84%
Pretax Income	-$12.99M	-$14.08M	-$47.62M
YoY Change	19.71%	21.63%	26.51%
Income Tax	-$20.05K	$210.3K	$358.5K
% Of Pretax Income
Net Earnings	-$12.97M	-$14.29M	-$47.98M
YoY Change	19.2%	21.95%	26.56%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.17		-$0.62
Diluted Earnings Per Share	-$0.17	-$183.3K	-$623.8K
COMMON SHARES
Basic Shares Outstanding	77.96M shares		76.91M shares
Diluted Shares Outstanding	77.98M shares		76.91M shares

Balance Sheet

Concept	2022 Q4	2022 Q3	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$143.6M	$149.2M	$149.2M
YoY Change	-4.98%	-1.94%	-1.94%
Cash & Equivalents	$143.6M	$149.2M	$149.2M
Short-Term Investments
Other Short-Term Assets	$655.6K	$354.2K	$354.2K
YoY Change	73.51%	-4.78%	-4.78%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$148.4M	$152.7M	$152.7M
YoY Change	-5.43%	-5.51%	-5.51%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$2.00	$3.00	$0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets	$148.4M	$152.7M	$152.7M
Total Long-Term Assets	$2.00	$3.00	$0.00
Total Assets	$148.4M	$152.7M	$152.7M
YoY Change	-5.43%	-5.51%	-5.51%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$5.288M	$3.825M	$3.825M
YoY Change	14.1%	-19.3%	-19.3%
Accrued Expenses	$7.043M	$5.945M	$5.945M
YoY Change	29.23%	5.88%	5.88%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$13.25M	$10.21M	$10.21M
YoY Change	25.83%	-5.42%	-5.42%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$13.25M	$10.21M	$10.21M
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$13.25M	$10.21M	$10.21M
YoY Change	25.83%	-5.42%	-5.42%
SHAREHOLDERS EQUITY
Retained Earnings	-$258.5M	-$245.6M
YoY Change		24.28%
Common Stock	$393.7M	$388.1M
YoY Change		11.38%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$135.1M	$142.5M	$142.5M
YoY Change
Total Liabilities & Shareholders Equity	$148.4M	$152.7M	$152.7M
YoY Change	-5.43%	-5.51%	-5.51%

Cashflow Statement

Concept	2022 Q4	2022 Q3	2022
OPERATING ACTIVITIES
Net Income	-$12.97M	-$14.29M	-$47.98M
YoY Change	19.2%	21.95%	26.56%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities	-$5.794M	-$4.044M	-$24.24M
YoY Change	65.5%	-47.31%	-20.23%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$20.98M
YoY Change			-86.78%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$258.2K	2.440K	$21.29M
YoY Change	-89.83%	-99.89%	-86.11%
NET CHANGE
Cash From Operating Activities	-$5.794M	-4.044M	-$24.24M
Cash From Investing Activities
Cash From Financing Activities	$258.2K	2.440K	$21.29M
Net Change In Cash	-$5.536M	-4.041M	-$2.950M
YoY Change	475.83%	-25.88%	-102.4%
FREE CASH FLOW
Cash From Operating Activities	-$5.794M	-$4.044M	-$24.24M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001314052
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022	avxl	Non Operating Income From Grants NonOperatingIncomeFromGrants		usd
CY2022	avxl	Deferred Grant Incomes DeferredGrantIncomes		usd
CY2020	avxl	Deferred Grant Incomes DeferredGrantIncomes		usd
CY2022	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises		usd
CY2020	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises		usd
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised		usd
CY2020	avxl	Commitment Shares Issued Shares Underterms Of Purchase Agreement2 CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2		usd
CY2020	avxl	Shares Issued Pursuant To Cashless Exercise Of Option In Shares SharesIssuedPursuantToCashlessExerciseOfOptionInShares		shares
CY2021	avxl	Commitment Shares Issued Shares Underterms Of Purchase Agreement2 CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2		usd
CY2022Q3	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2021Q3	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2020	avxl	Permanent Differences Relating To Stock Based Compensation PermanentDifferencesRelatingToStockBasedCompensation		usd
CY2022	avxl	Permanent Differences Relating To Section162m PermanentDifferencesRelatingToSection162m		usd
CY2020	avxl	Permanent Differences Relating To Section162m PermanentDifferencesRelatingToSection162m		usd
CY2022	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments		usd
CY2022	avxl	Adjustment To Tax Assets Based On Section382 AdjustmentToTaxAssetsBasedOnSection382		usd
CY2020	avxl	Adjustment To Tax Assets Based On Section382 AdjustmentToTaxAssetsBasedOnSection382		usd
CY2022	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate		usd
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-09-30
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--09-30
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	001-37606
CY2022	dei	Entity Registrant Name EntityRegistrantName	ANAVEX LIFE SCIENCES CORP.
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	98-0608404
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	630 5th Avenue
CY2022	dei	Entity Address Address Line2 EntityAddressAddressLine2	20th Floor
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	New York
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	NY
CY2022	dei	Entity Address Country EntityAddressCountry	US
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	10111
CY2022	dei	City Area Code CityAreaCode	844
CY2022	dei	Local Phone Number LocalPhoneNumber	689-3939
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	false
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q1	dei	Entity Public Float EntityPublicFloat	921000000	usd
CY2022Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	77961815	shares
CY2022	dei	Auditor Name AuditorName	GRANT THORNTON LLP
CY2022	dei	Auditor Location AuditorLocation	Hartford, Connecticut
CY2022	dei	Auditor Firm AuditorFirmId	248
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	149157861	usd
CY2021Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	152107745	usd
CY2022Q3	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	3192580	usd
CY2021Q3	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	9136831	usd
CY2022Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	354162	usd
CY2021Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	371914	usd
CY2022Q3	us-gaap	Assets Assets	152704603	usd
CY2021Q3	us-gaap	Assets Assets	161616490	usd
CY2022Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	3824777	usd
CY2021Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	4739781	usd
CY2022Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5944953	usd
CY2021Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5614774	usd
CY2022Q3	us-gaap	Deferred Rent Credit DeferredRentCredit	443831	usd
CY2021Q3	us-gaap	Deferred Rent Credit DeferredRentCredit	443831	usd
CY2022Q3	us-gaap	Liabilities Liabilities	10213561	usd
CY2021Q3	us-gaap	Liabilities Liabilities	10798386	usd
CY2022Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2021Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2021Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	77942815	shares
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	77942815	shares
CY2021Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	75918465	shares
CY2021Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	75918465	shares
CY2022Q3	us-gaap	Common Stock Value CommonStockValue	77944	usd
CY2021Q3	us-gaap	Common Stock Value CommonStockValue	75920	usd
CY2022Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	387976881	usd
CY2021Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	348328048	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-245563783	usd
CY2021Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-197585864	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	142491042	usd
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	150818104	usd
CY2022Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	152704603	usd
CY2021Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	161616490	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	13070068	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9017511	usd
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5856609	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	37915747	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	32983674	usd
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	25231623	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	-50985815	usd
CY2021	us-gaap	Operating Expenses OperatingExpenses	-42001185	usd
CY2020	us-gaap	Operating Expenses OperatingExpenses	-31088232	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-50985815	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-42001185	usd
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-31088232	usd
CY2021	avxl	Non Operating Income From Grants NonOperatingIncomeFromGrants	54100	usd
CY2020	avxl	Non Operating Income From Grants NonOperatingIncomeFromGrants	149888	usd
CY2022	avxl	Research And Development Incentive Income ResearchAndDevelopmentIncentiveIncome	3323011	usd
CY2021	avxl	Research And Development Incentive Income ResearchAndDevelopmentIncentiveIncome	4547099	usd
CY2020	avxl	Research And Development Incentive Income ResearchAndDevelopmentIncentiveIncome	4375025	usd
CY2022	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	946988	usd
CY2021	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	26261	usd
CY2020	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	179973	usd
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-903611	usd
CY2021	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-267344	usd
CY2020	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	125540	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	3366388	usd
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	4360116	usd
CY2020	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	4830426	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-47619427	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-37641069	usd
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-26257806	usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	358492	usd
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	267565	usd
CY2020	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	22664	usd
CY2022	avxl	Net Loss And Comprehensive Loss NetLossAndComprehensiveLoss	-47977919	usd
CY2021	avxl	Net Loss And Comprehensive Loss NetLossAndComprehensiveLoss	-37908634	usd
CY2020	avxl	Net Loss And Comprehensive Loss NetLossAndComprehensiveLoss	-26280470	usd
CY2022	avxl	Net Loss Per Share Basic And Diluted NetLossPerShareBasicAndDiluted	-0.62
CY2021	avxl	Net Loss Per Share Basic And Diluted NetLossPerShareBasicAndDiluted	-0.54
CY2020	avxl	Net Loss Per Share Basic And Diluted NetLossPerShareBasicAndDiluted	-0.45
CY2022	avxl	Weighted Average Number Of Shares Outstanding Basic And Diluted WeightedAverageNumberOfSharesOutstandingBasicAndDiluted	76909993
CY2021	avxl	Weighted Average Number Of Shares Outstanding Basic And Diluted WeightedAverageNumberOfSharesOutstandingBasicAndDiluted	69802960
CY2020	avxl	Weighted Average Number Of Shares Outstanding Basic And Diluted WeightedAverageNumberOfSharesOutstandingBasicAndDiluted	58194894
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-47977919	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-37908634	usd
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-26280470	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	18379242	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	8231403	usd
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	4876906	usd
CY2022	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	-5944251	usd
CY2021	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	4287491	usd
CY2020	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	2206595	usd
CY2022	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-1387	usd
CY2021	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-88290	usd
CY2020	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-57159	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-915004	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	750727	usd
CY2020	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	465722	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	330179	usd
CY2021	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	2298200	usd
CY2022	avxl	Shares Issued Pursuant To Exercise Of Stock Options SharesIssuedPursuantToExerciseOfStockOptions	1010190	usd
CY2022	avxl	Shares Issued Under Sales Agreement SharesIssuedUnderSalesAgreement	20984667	usd
CY2022	avxl	Less Share Issue Costs LessShareIssueCosts	-723242	usd
CY2020	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1800232	usd
CY2021	avxl	Deferred Grant Incomes DeferredGrantIncomes	-443831	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-24237864	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-30383674	usd
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-21287046	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	20984667	usd
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	153218762	usd
CY2020	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	28754198	usd
CY2022	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	706877	usd
CY2021	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	5550921	usd
CY2020	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	403764	usd
CY2021	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	1466500	usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1010190	usd
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	4108060	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	21287980	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	153242401	usd
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	28350434	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-2949884	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	122858727	usd
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	7063388	usd
CY2021Q3	us-gaap	Cash Cash	152107745	usd
CY2020Q3	us-gaap	Cash Cash	29249018	usd
CY2019Q3	us-gaap	Cash Cash	22185630	usd
CY2022Q3	us-gaap	Cash Cash	149157861	usd
CY2021Q3	us-gaap	Cash Cash	152107745	usd
CY2020Q3	us-gaap	Cash Cash	29249018	usd
CY2022	avxl	Cash Paid For State And Local Minimum Income Taxes CashPaidForStateAndLocalMinimumIncomeTaxes	326903	usd
CY2021	avxl	Cash Paid For State And Local Minimum Income Taxes CashPaidForStateAndLocalMinimumIncomeTaxes	139531	usd
CY2020	avxl	Cash Paid For State And Local Minimum Income Taxes CashPaidForStateAndLocalMinimumIncomeTaxes	22664	usd
CY2019Q3	us-gaap	Stockholders Equity StockholdersEquity	20289699	usd
CY2020	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	21254298	usd
CY2020	avxl	Shares Issued Under Sales Agreement SharesIssuedUnderSalesAgreement	7499900	usd
CY2020	avxl	Less Share Issue Costs LessShareIssueCosts	-403764	usd
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4876906	usd
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-26280470	usd
CY2020Q3	us-gaap	Stockholders Equity StockholdersEquity	27236569	usd
CY2021	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	24111198	usd
CY2021	avxl	Shares Issued Pursuant To Exercise Of Stock Options SharesIssuedPursuantToExerciseOfStockOptions	4108060	usd
CY2021	avxl	Shares Issued Under Sales Agreement SharesIssuedUnderSalesAgreement	79107550	usd
CY2021	avxl	Less Share Issue Costs LessShareIssueCosts	-2437523	usd
CY2021	avxl	Shares Issued Pursuant To Registered Direct Offering SharesIssuedPursuantToRegisteredDirectOffering	50000013	usd
CY2021	avxl	Less Shares Issue Costs LessSharesIssueCosts	-3097032	usd
CY2021	avxl	Shares Issued Pusuant To Exercise Of Warrants SharesIssuedPusuantToExerciseOfWarrants	1466500	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	8231403	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-37908634	usd
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	150818104	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	18379242	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-47977919	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	142491042	usd
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	13329616	shares
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	11540903	shares
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	10576266	shares
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_849_eus-gaap--UseOfEstimates_z8gKMmY1HLRe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_865_zWG3EmOoh2sk">Use of Estimates</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><b><i> </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses in the reporting period. The Company regularly evaluates estimates and assumptions related to accounting for research and development costs, incentive income receivable, valuation and recoverability of deferred tax assets, stock-based compensation and loss contingencies. The Company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the book values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/>
CY2022Q3	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	usd
CY2022	us-gaap	Revenue Recognition Incentives RevenueRecognitionIncentives	<p id="xdx_849_eus-gaap--RevenueRecognitionIncentives_zsVE6ZiohaM8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_861_zTbyIPlIwXve">Research and Development Incentive Income</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i> </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company is eligible to obtain certain research and development tax credits, including the Australian research and development tax incentive credit (the “Australia R&D credit”) through a program administered through the Australian Tax Office (the “ATO”) and AusIndustry, a division of the Australian Government’s Department of Industry, Innovation and Science (“AusIndustry”), which provides for a cash refund based on a percentage of eligible research and development activities undertaken in Australia by the Company’s wholly owned subsidiary, Anavex Australia. Anavex Australia is also eligible under the Australia R&D credit program to receive the cash refund for certain research and development expenses incurred by Anavex Australia outside of Australia, to the extent such expenses are pre-approved by AusIndustry pursuant to an advanced overseas finding application.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Australia R&D credit program is available to eligible companies with an annual aggregate revenue of less than $20.0 million Australian during the reimbursable period.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The tax incentives are available on the basis of specific criteria with which the Company must comply. Although the tax incentive may be administered through the local tax authority, the Company has accounted for the incentives outside of the scope of ASC Topic 740, Income Taxes (“ASC 740”), since the incentives are not linked to the Company’s taxable income and can be realized regardless of whether the Company has generated taxable income in the respective jurisdictions.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">With respect to the Australia R&D credit, as there is no authoritative guidance under GAAP for accounting for grants to for-profit business entities, the Company accounts for the grant by analogy to IAS20 <i>Accounting for Government Grants and Disclosure of Government Assistance</i> (“IAS 20”). The Company recognizes the Research and Development Incentive income as it incurs costs eligible for reimbursement under the Australia R&D credit Program when it is reasonably assured that the cash incentive will be received, as evidenced through enrollment in the program and when the applicable conditions under the program have been met. The Company accrues for the amount of cash refund it expects to receive in relation to research and development expenses outside of Australia only to the extent it has received advanced approval from AusIndustry, pursuant to an approved advanced overseas finding application.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition, Anavex Australia and Anavex Canada incur Goods and Services Tax (GST) on certain services provided by local vendors. As a domestic entity in those jurisdictions, Anavex Australia and Anavex Canada are entitled to a refund of the GST paid. Similarly, Anavex Germany incurs Value Added Tax (VAT) on certain services provided by local vendors, to which it is entitled to a refund of such VAT paid. The Company’s estimate of the amount of cash refund it expects to receive related to GST and VAT incurred is included in Incentive and tax receivables in the accompanying consolidated balance sheets.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
CY2022Q3	us-gaap	Liability For Uncertain Tax Positions Current LiabilityForUncertainTaxPositionsCurrent	0	usd
CY2022	us-gaap	Income Tax Examination Penalties And Interest Expense IncomeTaxExaminationPenaltiesAndInterestExpense	0	usd
CY2021	us-gaap	Income Tax Examination Penalties And Interest Expense IncomeTaxExaminationPenaltiesAndInterestExpense	0	usd
CY2022	avxl	Grant Income GrantIncome	0	usd
CY2021	avxl	Grant Income GrantIncome	497931	usd
CY2020	avxl	Grant Income GrantIncome	0	usd
CY2022Q3	avxl	Clinical Site Costs And Patient Visits ClinicalSiteCostsAndPatientVisits	2031105	usd
CY2021Q3	avxl	Clinical Site Costs And Patient Visits ClinicalSiteCostsAndPatientVisits	2035800	usd
CY2022Q3	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	1297337	usd
CY2021Q3	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	1201903	usd
CY2022Q3	avxl	Fixed Contract Accruals FixedContractAccruals	417414	usd
CY2021Q3	avxl	Fixed Contract Accruals FixedContractAccruals	649649	usd
CY2022Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2199097	usd
CY2021Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1727422	usd
CY2022Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5944953	usd
CY2021Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5614774	usd
CY2022	avxl	Non Operating Income From Grant NonOperatingIncomeFromGrant	0	usd
CY2021	avxl	Non Operating Income From Grant NonOperatingIncomeFromGrant	54100	usd
CY2020	avxl	Non Operating Income From Grant NonOperatingIncomeFromGrant	0	usd
CY2022Q3	avxl	Deferred Grant Income DeferredGrantIncome	443831	usd
CY2021Q3	avxl	Deferred Grant Income DeferredGrantIncome	443831	usd
CY2017	avxl	Non Operating Income From Grant NonOperatingIncomeFromGrant	597886	usd
CY2020	avxl	Non Operatings Income From Grant NonOperatingsIncomeFromGrant	149888	usd
CY2022	us-gaap	Research And Development Arrangement Contract To Perform For Others Compensation Earned ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned	3323011	usd
CY2021	us-gaap	Research And Development Arrangement Contract To Perform For Others Compensation Earned ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned	4547099	usd
CY2020	us-gaap	Research And Development Arrangement Contract To Perform For Others Compensation Earned ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned	4375025	usd
CY2022Q3	avxl	Sales Of Agreement Amount SalesOfAgreementAmount	142407882	usd
CY2021Q3	avxl	Sales Of Agreement Amount SalesOfAgreementAmount	163392550	usd
CY2022	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	72865	usd
CY2021	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	130784	usd
CY2020	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	233423	usd
CY2022	us-gaap	Pension Contributions PensionContributions	158112	usd
CY2021	us-gaap	Pension Contributions PensionContributions	128856	usd
CY2020	us-gaap	Pension Contributions PensionContributions	98058	usd
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	160000	shares
CY2022	avxl	Option Issued OptionIssued	2058000	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	4.69
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	2.54
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	2.55
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y4M24D
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y9M18D
CY2022	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2	P5Y1M6D
CY2021	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2	P5Y6M
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	18379242	usd
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	8231403	usd
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4876906	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	18379242	usd
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	8231403	usd
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4876906	usd
CY2022Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	19032000	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0311	pure
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0073	pure
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0157	pure
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y6M25D
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y8M26D
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y6M10D
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.8417	pure
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.9343	pure
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.9599	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.0000	pure
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.0000	pure
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.0000	pure
CY2020	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-5519000	usd
CY2022	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	-170000	usd
CY2021	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	-353000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-40001893	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-28850926	usd
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-18096148	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-7617534	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-8790143	usd
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-8161658	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-47619427	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-37641069	usd
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-26257806	usd
CY2022Q3	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	46208000	usd
CY2021Q3	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	34982000	usd
CY2022Q3	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	2182000	usd
CY2021Q3	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	1577000	usd
CY2022Q3	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	13373000	usd
CY2021Q3	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	10453000	usd
CY2022Q3	avxl	Deferred Tax Assets Unpaid Charges DeferredTaxAssetsUnpaidCharges	894000	usd
CY2021Q3	avxl	Deferred Tax Assets Unpaid Charges DeferredTaxAssetsUnpaidCharges	89000	usd
CY2022Q3	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	388000	usd
CY2021Q3	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	323000	usd
CY2022Q3	us-gaap	Deferred Tax Assets Unrealized Currency Losses DeferredTaxAssetsUnrealizedCurrencyLosses	44000	usd
CY2021Q3	us-gaap	Deferred Tax Assets Unrealized Currency Losses DeferredTaxAssetsUnrealizedCurrencyLosses	62000	usd
CY2022Q3	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	63089000	usd
CY2021Q3	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	47486000	usd
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-10000000	usd
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-7934000	usd
CY2020	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	-723000	usd
CY2022	avxl	Permanent Differences Relating To Stock Based Compensation PermanentDifferencesRelatingToStockBasedCompensation	-714000	usd
CY2021	avxl	Permanent Differences Relating To Stock Based Compensation PermanentDifferencesRelatingToStockBasedCompensation	-4379000	usd
CY2021	avxl	Permanent Differences Relating To Section162m PermanentDifferencesRelatingToSection162m	816000	usd
CY2021	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	741000	usd
CY2020	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	35000	usd
CY2021	avxl	Adjustment To Tax Assets Based On Section382 AdjustmentToTaxAssetsBasedOnSection382	3330000	usd
CY2022	avxl	Income Tax Reconciliation Nondeductible Expense Research And Development Credit Net IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCreditNet	232000	usd
CY2021	avxl	Income Tax Reconciliation Nondeductible Expense Research And Development Credit Net IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCreditNet	1042000	usd
CY2020	avxl	Income Tax Reconciliation Nondeductible Expense Research And Development Credit Net IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCreditNet	1267000	usd
CY2022	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-4975000	usd
CY2021	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-7022000	usd
CY2020	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-2911000	usd
CY2022	us-gaap	Income Tax Reconciliation Prior Year Income Taxes IncomeTaxReconciliationPriorYearIncomeTaxes	24000	usd
CY2021	us-gaap	Income Tax Reconciliation Prior Year Income Taxes IncomeTaxReconciliationPriorYearIncomeTaxes	48000	usd
CY2020	us-gaap	Income Tax Reconciliation Prior Year Income Taxes IncomeTaxReconciliationPriorYearIncomeTaxes	373000	usd
CY2021	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	216000	usd
CY2020	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	36000	usd
CY2022	us-gaap	Taxes Excluding Income And Excise Taxes TaxesExcludingIncomeAndExciseTaxes	358492	usd
CY2021	us-gaap	Taxes Excluding Income And Excise Taxes TaxesExcludingIncomeAndExciseTaxes	267565	usd
CY2020	us-gaap	Taxes Excluding Income And Excise Taxes TaxesExcludingIncomeAndExciseTaxes	22664	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	15603000	usd
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	13495000	usd
CY2020	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	7442000	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	358492	usd
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	267565	usd
CY2020	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	22664	usd
CY2022	avxl	Operating Loss Carry Forwards Expiration Year OperatingLossCarryForwardsExpirationYear	2036
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense Research And Development IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment	2200000	usd
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense Research And Development IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment	1600000	usd
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	3300000	usd

Files In Submission

Name	View Source	Status
0001731122-22-002062-index-headers.html	Edgar Link	pending
0001731122-22-002062-index.html	Edgar Link	pending
0001731122-22-002062.txt	Edgar Link	pending
0001731122-22-002062-xbrl.zip	Edgar Link	pending
avxl-20220930.xsd	Edgar Link	pending
e4251_10k.htm	Edgar Link	pending
e4251_ex23-1.htm	Edgar Link	pending
e4251_ex23-2.htm	Edgar Link	pending
e4251_ex31-1.htm	Edgar Link	pending
e4251_ex31-2.htm	Edgar Link	pending
e4251_ex32-1.htm	Edgar Link	pending
e4251_ex4-1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
image_001.jpg	Edgar Link	pending
image_002.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
avxl-20220930_cal.xml	Edgar Link	unprocessable
avxl-20220930_def.xml	Edgar Link	unprocessable
avxl-20220930_pre.xml	Edgar Link	unprocessable
avxl-20220930_lab.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
e4251_10k_htm.xml	Edgar Link	completed
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$AVXL
Anavex Life Sciences Corp Stock $avxl

2022 Q4 Form 10-K Financial Statement

#000173112222002062 Filed on November 28, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AVXL Anavex Life Sciences Corp Stock $avxl

2022 Q4 Form 10-K Financial Statement

#000173112222002062 Filed on November 28, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AVXL
Anavex Life Sciences Corp Stock $avxl